{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T23:47:46Z","timestamp":1794872866509,"version":"4.9.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prolongation of the QT interval in the ECG is a critical finding that signifies an extended duration from the onset of ventricular depolarization to the end of ventricular repolarization. It can predispose patients to life-threatening arrhythmias, such as Torsades de Pointes (TdP). Long QT syndromes (LQTS) are defined by mutations in ion channel genes, particularly those encoding cardiac potassium and sodium channels and are characterized by a significant risk for sudden cardiac death if untreated. However, besides these clearly defined entities various medications have been implicated in causing QT interval prolongation. There is increasing evidence for a genetically determined risk for drug-induced QT prolongation. In addition, due to numerous clinical factors influencing the QT interval, QT prolongation increases the risk of TdP particularly in multi-morbid patients necessitating vigilant monitoring in at-risk populations. This review gives an overview of mechanisms and conditions which induce QT prolongation, the clinical assessment of QT interval duration, thereby highlighting quantitative variations in measurement techniques and heart-rate correction, as well as in demographic interpretation of normal values. The risk of cardiac arrhythmia is discussed, in both patients with congenital LQTS and acquired QT prolongation, along with influencing pharmacokinetic\/pharmacodynamic, non-pharmacologic and genetic risk factors for TdP. Finally, clinical implications for individual patient management, including risk-adapted drug-prescription and use of ECG monitoring to mitigate the risks associated with QT prolongation, are summarized. Understanding the interplay between pharmacokinetics, pharmacodynamics, genetic predisposition and co-morbidities is essential for optimizing treatment in the context of prolonged QT intervals, preventing adverse cardiovascular events, and improving cardiac safety. Comprehensive drug labelling regarding exposure-QT relationships and available pharmacovigilance data are important sources of information enhancing patient safety.<\/jats:p>","DOI":"10.1007\/s10928-025-10010-x","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:19:41Z","timestamp":1762543181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["QT interval prolongation: clinical assessment, risk factors and quantitative pharmacological considerations"],"prefix":"10.1007","volume":"52","author":[{"given":"Verena","family":"Gotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Donner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"10010_CR1","doi-asserted-by":"publisher","unstructured":"Rautaharju PM, Surawicz B, Gettes LS (2009) AHA\/ACCF\/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, t and u waves, and the QT interval: A scientific statement from the American heart association electrocardiography and arrhythmias C. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.191096. Circulation 119:","DOI":"10.1161\/CIRCULATIONAHA.108.191096"},{"key":"10010_CR2","doi-asserted-by":"publisher","DOI":"10.1100\/2012\/212178","author":"EM Kallergis","year":"2012","unstructured":"Kallergis EM, Goudis CA, Simantirakis EN et al (2012) Mechanisms, risk factors, and management of acquired long Qt syndrome: a comprehensive review. Sci World J. https:\/\/doi.org\/10.1100\/2012\/212178","journal-title":"Sci World J"},{"key":"10010_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijcha.2016.11.006","volume":"14","author":"G Tse","year":"2017","unstructured":"Tse G, Chan YWF, Keung W, Yan BP (2017) Electrophysiological mechanisms of long and short QT syndromes. IJC Heart & Vasculature 14:8\u201313. https:\/\/doi.org\/10.1016\/j.ijcha.2016.11.006","journal-title":"IJC Heart & Vasculature"},{"key":"10010_CR4","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1046\/J.1365-2125.2002.01627.X","volume":"54","author":"RR Shah","year":"2002","unstructured":"Shah RR (2002) The significance of QT interval in drug development. Br J Clin Pharmacol 54:188\u2013202. https:\/\/doi.org\/10.1046\/J.1365-2125.2002.01627.X","journal-title":"Br J Clin Pharmacol"},{"key":"10010_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/PDS.1707","volume":"18","author":"YL Lin","year":"2009","unstructured":"Lin YL, Kung MF (2009) Magnitude of QT prolongation associated with a higher risk of Torsades de pointes. Pharmacoepidemiol Drug Saf 18:235\u2013239. https:\/\/doi.org\/10.1002\/PDS.1707","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10010_CR6","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1093\/EUROPACE\/EUZ058","volume":"21","author":"C Gibbs","year":"2019","unstructured":"Gibbs C, Thalamus J, Kristoffersen DT et al (2019) QT prolongation predicts short-term mortality independent of comorbidity. Europace 21:1254\u20131260. https:\/\/doi.org\/10.1093\/EUROPACE\/EUZ058","journal-title":"Europace"},{"key":"10010_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90024-7","author":"DJ MacNeil","year":"1993","unstructured":"MacNeil DJ, Davies RO, Deitchman D (1993) Clinical safety profile of Sotalol in the treatment of arrhythmias. Am J Cardiol. https:\/\/doi.org\/10.1016\/0002-9149(93)90024-7","journal-title":"Am J Cardiol"},{"key":"10010_CR8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.14740\/cr1143","volume":"11","author":"JC Somberg","year":"2020","unstructured":"Somberg JC, Vinks AA, Dong M, Molnar J (2020) Model-informed development of Sotalol loading and dose escalation employing an intravenous infusion. Cardiol Res 11:294\u2013304. https:\/\/doi.org\/10.14740\/cr1143","journal-title":"Cardiol Res"},{"key":"10010_CR9","unstructured":"ICH E14 Guideline (2005) Clinical evaluation of QT\/QTc interval prolongation and. proarrhythmic potential for non-antiarrhythmic drugs"},{"key":"10010_CR10","doi-asserted-by":"publisher","first-page":"4364","DOI":"10.1111\/bph.13218","volume":"172","author":"V Gotta","year":"2015","unstructured":"Gotta V, Cools F, van Ammel K et al (2015) Inter-study variability of preclinical in vivo safety studies and translational exposure-QTc relationships - a PKPD meta-analysis. Br J Pharmacol 172:4364\u20134379. https:\/\/doi.org\/10.1111\/bph.13218","journal-title":"Br J Pharmacol"},{"key":"10010_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.270","volume":"4","author":"V Gotta","year":"2016","unstructured":"Gotta V, Yu Z, Cools F et al (2016) Application of a systems pharmacology model for translational prediction of hERG-mediated QTc prolongation. Pharmacol Res Perspect 4:e00270. https:\/\/doi.org\/10.1002\/prp2.270","journal-title":"Pharmacol Res Perspect"},{"key":"10010_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/J.CCEP.2016.01.004","volume":"8","author":"L Chen","year":"2016","unstructured":"Chen L, Sampson KJ, Kass RS (2016) Cardiac delayed rectifier potassium channels in health and disease. Card Electrophysiol Clin 8:307. https:\/\/doi.org\/10.1016\/J.CCEP.2016.01.004","journal-title":"Card Electrophysiol Clin"},{"key":"10010_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS22158090","author":"D Baracaldo-Santamar\u00eda","year":"2021","unstructured":"Baracaldo-Santamar\u00eda D, Llin\u00e1s-Caballero K, Corso-Ramirez JM et al (2021) Genetic and molecular aspects of drug-induced QT interval prolongation. Int J Mol Sci. https:\/\/doi.org\/10.3390\/IJMS22158090","journal-title":"Int J Mol Sci"},{"key":"10010_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1172666","author":"LJ Hoek","year":"2023","unstructured":"Hoek LJ, Brouwer JLP, Voors AA, Maass AH (2023) Smart devices to measure and monitor QT intervals. Front Cardiovasc Med. https:\/\/doi.org\/10.3389\/fcvm.2023.1172666","journal-title":"Front Cardiovasc Med"},{"key":"10010_CR15","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/europace\/euac038","volume":"24","author":"E Svennberg","year":"2022","unstructured":"Svennberg E, Tjong F, Goette A et al (2022) How to use digital devices to detect and manage arrhythmias: an EHRA practical guide. Europace 24:979\u20131005. https:\/\/doi.org\/10.1093\/europace\/euac038","journal-title":"Europace"},{"key":"10010_CR16","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1161\/CIRCULATIONAHA.118.033943","volume":"138","author":"AS Vink","year":"2018","unstructured":"Vink AS, Neumann B, Lieve KVV et al (2018) Determination and interpretation of the QT interval: comprehensive analysis of a large cohort of long QT syndrome patients and controls. Circulation 138:2345\u20132358. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.033943","journal-title":"Circulation"},{"key":"10010_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1088\/0967-3334\/21\/2\/309","volume":"21","author":"RH Ireland","year":"2000","unstructured":"Ireland RH, Robinson RTCE, Heller SR et al (2000) Measurement of high resolution ECG QT interval during controlled euglycaemia and hypoglycaemia. Physiol Meas 21:295\u2013303. https:\/\/doi.org\/10.1088\/0967-3334\/21\/2\/309","journal-title":"Physiol Meas"},{"key":"10010_CR18","unstructured":"Committee for Human Medicinal Products, EMA (2020) ICH guideline E14\/S7B: clinical and nonclinical evaluation of QT\/QTc. Interval Prolongation and Proarrhythmic Potential - questions and answers"},{"key":"10010_CR19","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v7.i6.315","volume":"7","author":"SW Rabkin","year":"2015","unstructured":"Rabkin SW (2015) Nomenclature, categorization and usage of formulae to adjust QT interval for heart rate. World J Cardiol 7:315. https:\/\/doi.org\/10.4330\/wjc.v7.i6.315","journal-title":"World J Cardiol"},{"key":"10010_CR20","unstructured":"Bazett HC (1920) An analysis of the time-relations of electrocardiograms. Heart 7:353\u2013370"},{"key":"10010_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1920.tb18266.x","author":"L Fridericia","year":"1920","unstructured":"Fridericia LS (1921)\u00a0Die Systolendauer im Elektrokardiogramm bei Normalem Menschen und bei Herzkranken. Acta Med Scand 54:17\u201350. https:\/\/doi.org\/10.1111\/j.0954-6820.1920.tb18266.x","journal-title":"Acta Med Scand 54:17-50."},{"key":"10010_CR22","unstructured":"Hodges M (1983) Bazett\u00b4s QT correction reviewed: evidence that a linear QT correction for heart rate is better. J Am Coll Cardiol 1:694"},{"key":"10010_CR23","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/0002-9149(92)90562-D","volume":"70","author":"A Sagie","year":"1992","unstructured":"Sagie A, Larson MG, Goldberg RJ et al (1992) An improved method for adjusting the QT interval for heart rate (the Framingham heart study). Am J Cardiol 70:797\u2013801. https:\/\/doi.org\/10.1016\/0002-9149(92)90562-D","journal-title":"Am J Cardiol"},{"key":"10010_CR24","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1046\/j.1540-8167.2002.01211.x","volume":"13","author":"PM Rautaharju","year":"2002","unstructured":"Rautaharju PM, Zhang ZM (2002) Linearly scaled, rate-invariant normal limits for QT interval: eight decades of incorrect application of power functions. J Cardiovasc Electrophysiol 13:1211\u20131218. https:\/\/doi.org\/10.1046\/j.1540-8167.2002.01211.x","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10010_CR25","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1111\/j.1540-8159.1999.tb00635.x","volume":"22","author":"K Aytemir","year":"1999","unstructured":"Aytemir K, Maarouf N, Gallagher MM et al (1999) Comparison of formulae for heart rate correction of QT interval in exercise electrocardiograms. Pacing Clin Electrophysiol 22:1397\u20131401. https:\/\/doi.org\/10.1111\/j.1540-8159.1999.tb00635.x","journal-title":"Pacing Clin Electrophysiol"},{"key":"10010_CR26","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1111\/j.1540-8159.2009.02513.x","volume":"32","author":"RL Woosley","year":"2009","unstructured":"Woosley RL, Romero K (2009) Time to replace bazett\u2019s QT-correction. Pacing Clin Electrophysiol 32:1379\u20131380. https:\/\/doi.org\/10.1111\/j.1540-8159.2009.02513.x","journal-title":"Pacing Clin Electrophysiol"},{"key":"10010_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/heart.86.2.199","volume":"86","author":"A Benatar","year":"2001","unstructured":"Benatar A, Decraene T (2001) Comparison of formulae for heart rate correction of QT interval in exercise ECGS from healthy children. Heart 86:199\u2013202. https:\/\/doi.org\/10.1136\/heart.86.2.199","journal-title":"Heart"},{"key":"10010_CR28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.amjms.2015.11.007","volume":"351","author":"SW Rabkin","year":"2016","unstructured":"Rabkin SW, Cheng XB (2016) Newer QT correction formulae to correct QT for heart rate changes during exercise. Am J Med Sci 351:133\u2013139. https:\/\/doi.org\/10.1016\/j.amjms.2015.11.007","journal-title":"Am J Med Sci"},{"key":"10010_CR29","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/15563650.2018.1510501","volume":"57","author":"R Othong","year":"2019","unstructured":"Othong R, Wattanasansomboon S, Kruutsaha T et al (2019) Utility of QT interval corrected by Rautaharju method to predict drug-induced torsade de pointes. Clin Toxicol 57:234\u2013239. https:\/\/doi.org\/10.1080\/15563650.2018.1510501","journal-title":"Clin Toxicol"},{"key":"10010_CR30","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","volume":"45","author":"C Garnett","year":"2018","unstructured":"Garnett C, Bonate PL, Dang Q et al (2018) Scientific white paper on concentration-QTc modeling. J Pharmacokinet Pharmacodyn 45:383\u2013397. https:\/\/doi.org\/10.1007\/s10928-017-9558-5","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10010_CR31","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.ahj.2012.02.023","volume":"163","author":"CE Garnett","year":"2012","unstructured":"Garnett CE, Zhu H, Malik M et al (2012) Methodologies to characterize the QT\/corrected QT interval in the presence of drug-induced heart rate changes or other autonomic effects. Am Heart J 163:912\u2013930. https:\/\/doi.org\/10.1016\/j.ahj.2012.02.023","journal-title":"Am Heart J"},{"key":"10010_CR32","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/europace\/euaa143","volume":"23","author":"MM P\u00e6rregaard","year":"2021","unstructured":"P\u00e6rregaard MM, Hvidemose SO, Pihl C et al (2021) Defining the normal QT interval in newborns: the natural history and reference values for the first 4 weeks of life. Europace 23:278\u2013286. https:\/\/doi.org\/10.1093\/europace\/euaa143","journal-title":"Europace"},{"key":"10010_CR33","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.119.008253","volume":"13","author":"A Bratincs\u00e1k","year":"2020","unstructured":"Bratincs\u00e1k A, Kimata C, Limm-Chan BN et al (2020) Electrocardiogram standards for children and young adults using Z -scores. Circulation: Arrhythmia and Electrophysiology 13:E008253. https:\/\/doi.org\/10.1161\/CIRCEP.119.008253","journal-title":"Circulation: Arrhythmia and Electrophysiology"},{"key":"10010_CR34","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1053\/EUHJ.2000.2399","volume":"22","author":"PR Rijnbeek","year":"2001","unstructured":"Rijnbeek PR, Witsenburg M, Schrama E et al (2001) New normal limits for the paediatric electrocardiogram. Eur Heart J 22:702\u2013711. https:\/\/doi.org\/10.1053\/EUHJ.2000.2399","journal-title":"Eur Heart J"},{"key":"10010_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/J.CPCARDIOL.2021.100882","author":"G Gutierrez","year":"2022","unstructured":"Gutierrez G, Wamboldt R, Baranchuk A (2022) The impact of testosterone on the QT interval: a systematic review. Curr Probl Cardiol. https:\/\/doi.org\/10.1016\/J.CPCARDIOL.2021.100882","journal-title":"Curr Probl Cardiol"},{"key":"10010_CR36","doi-asserted-by":"crossref","unstructured":"Donner B (2019) Kapitel 15, kardiologie. In: Mayatepek E (ed) Lehrbuch P\u00e4diatrie. Elsevier, pp 439\u2013484","DOI":"10.1016\/B978-3-437-21661-9.00015-7"},{"key":"10010_CR37","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00962.2001","author":"P Smetana","year":"2002","unstructured":"Smetana P, Batchvarov VN, Hnatkova K et al (2002) Sex differences in repolarization homogeneity and its circadian pattern. American Journal of Physiology-Heart and Circulatory Physiology. https:\/\/doi.org\/10.1152\/ajpheart.00962.2001","journal-title":"American Journal of Physiology-Heart and Circulatory Physiology"},{"key":"10010_CR38","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/jcph.2301","volume":"63","author":"V Gotta","year":"2023","unstructured":"Gotta V, Bachmann S, Pfister M, Donner B (2023) Characterizing associations of QTc interval with nocturnal glycemic control in children with type 1 diabetes. J Clin Pharmacol 63:1147\u20131155. https:\/\/doi.org\/10.1002\/jcph.2301","journal-title":"J Clin Pharmacol"},{"key":"10010_CR39","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10928-021-09744-1","volume":"48","author":"B Wi\u015bniowska","year":"2021","unstructured":"Wi\u015bniowska B, Bielecka ZM, Polak S (2021) How circadian variability of the heart rate and plasma electrolytes concentration influence the cardiac electrophysiology \u2013 model-based case study. J Pharmacokinet Pharmacodyn 48:387\u2013399. https:\/\/doi.org\/10.1007\/s10928-021-09744-1","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10010_CR40","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1161\/CIRCRESAHA.109.206201","volume":"105","author":"TA Martino","year":"2009","unstructured":"Martino TA, Sole MJ (2009) Molecular time: an often overlooked dimension to cardiovascular disease. Circ Res 105:1047\u20131061. https:\/\/doi.org\/10.1161\/CIRCRESAHA.109.206201","journal-title":"Circ Res"},{"key":"10010_CR41","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/jcph.1129","volume":"58","author":"JR Turner","year":"2018","unstructured":"Turner JR, Rodriguez I, Mantovani E et al (2018) Drug-induced proarrhythmia and torsade de pointes: a primer for students and practitioners of medicine and pharmacy. J Clin Pharmacol 58:997\u20131012. https:\/\/doi.org\/10.1002\/jcph.1129","journal-title":"J Clin Pharmacol"},{"key":"10010_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/children11050582","volume":"11","author":"E Balestra","year":"2024","unstructured":"Balestra E, Bobbo M, Cittar M et al (2024) Congenital long QT syndrome in children and adolescents: A general overview. Children 11:1\u201314. https:\/\/doi.org\/10.3390\/children11050582","journal-title":"Children"},{"key":"10010_CR43","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/nejmoa022147","volume":"348","author":"SG Priori","year":"2003","unstructured":"Priori SG, Schwartz PJ, Napolitano C et al (2003) Risk stratification in the long-QT syndrome. N Engl J Med 348:1866\u20131874. https:\/\/doi.org\/10.1056\/nejmoa022147","journal-title":"N Engl J Med"},{"key":"10010_CR44","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","volume":"43","author":"K Zeppenfeld","year":"2022","unstructured":"Zeppenfeld K, Tfelt-Hansen J, De Riva M et al (2022) 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 43:3997\u20134126. https:\/\/doi.org\/10.1093\/eurheartj\/ehac262","journal-title":"Eur Heart J"},{"key":"10010_CR45","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.jacc.2018.01.078","volume":"71","author":"A Mazzanti","year":"2018","unstructured":"Mazzanti A, Maragna R, Vacanti G et al (2018) Interplay between genetic substrate, QTc duration, and arrhythmia risk in patients with long QT syndrome. J Am Coll Cardiol 71:1663\u20131671. https:\/\/doi.org\/10.1016\/j.jacc.2018.01.078","journal-title":"J Am Coll Cardiol"},{"key":"10010_CR46","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1161\/CIRCULATIONAHA.111.062182","volume":"124","author":"PJ Schwartz","year":"2011","unstructured":"Schwartz PJ, Crotti L (2011) QTc behavior during exercise and genetic testing for the long-QT syndrome. Circulation 124:2181\u20132184. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.062182","journal-title":"Circulation"},{"key":"10010_CR47","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1001\/jamacardio.2020.7422","volume":"6","author":"JM Bos","year":"2021","unstructured":"Bos JM, Attia ZI, Albert DE et al (2021) Use of artificial intelligence and deep neural networks in evaluation of patients with electrocardiographically concealed long QT syndrome from the surface 12-lead electrocardiogram. JAMA Cardiol 6:532\u2013538. https:\/\/doi.org\/10.1001\/jamacardio.2020.7422","journal-title":"JAMA Cardiol"},{"key":"10010_CR48","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.1093\/eurheartj\/ehab649","volume":"42","author":"ZI Attia","year":"2021","unstructured":"Attia ZI, Harmon DM, Behr ER, Friedman PA (2021) Application of artificial intelligence to the electrocardiogram. Eur Heart J 42:4717\u20134730. https:\/\/doi.org\/10.1093\/eurheartj\/ehab649","journal-title":"Eur Heart J"},{"key":"10010_CR49","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1001\/jamacardio.2024.0039","volume":"9","author":"R Jiang","year":"2024","unstructured":"Jiang R, Cheung CC, Garcia-Montero M et al (2024) Deep learning-augmented ECG analysis for screening and genotype prediction of congenital long QT syndrome. JAMA Cardiol 9:377\u2013384. https:\/\/doi.org\/10.1001\/jamacardio.2024.0039","journal-title":"JAMA Cardiol"},{"key":"10010_CR50","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1093\/europace\/eur245","volume":"13","author":"MJ Ackerman","year":"2011","unstructured":"Ackerman MJ, Priori SG, Willems S et al (2011) HRS\/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Europace 13:1077\u20131109. https:\/\/doi.org\/10.1093\/europace\/eur245","journal-title":"Europace"},{"key":"10010_CR51","doi-asserted-by":"publisher","unstructured":"Went TR, Sultan W, Sapkota A et al (2021) A systematic review on the role of \u0392eta-Blockers in reducing cardiac arrhythmias in long QT syndrome subtypes 1\u20133. https:\/\/doi.org\/10.7759\/cureus.17632. Cureus","DOI":"10.7759\/cureus.17632"},{"key":"10010_CR52","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1161\/CIRCULATIONAHA.124.068959","volume":"150","author":"L Crotti","year":"2024","unstructured":"Crotti L, Neves R, Dagradi F et al (2024) Therapeutic efficacy of mexiletine for long QT syndrome type 2: evidence from human induced pluripotent stem cell-derived cardiomyocytes, transgenic rabbits, and patients. Circulation 150:531\u2013543. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.068959","journal-title":"Circulation"},{"key":"10010_CR53","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/heartjnl-2020-318259","volume":"108","author":"AAM Wilde","year":"2022","unstructured":"Wilde AAM, Amin AS, Postema PG (2022) Diagnosis, management and therapeutic strategies for congenital long QT syndrome. Heart 108:332\u2013338. https:\/\/doi.org\/10.1136\/heartjnl-2020-318259","journal-title":"Heart"},{"key":"10010_CR54","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/164_2021_455","volume":"267","author":"S Su","year":"2021","unstructured":"Su S, Sun J, Wang Y, Xu Y (2021) Cardiac hERG K\u2009+\u2009Channel as safety and Pharmacological target. Handb Exp Pharmacol 267:139\u2013166. https:\/\/doi.org\/10.1007\/164_2021_455","journal-title":"Handb Exp Pharmacol"},{"key":"10010_CR55","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/clpt.2014.155","volume":"96","author":"L Johannesen","year":"2014","unstructured":"Johannesen L, Vicente J, Mason JW et al (2014) Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil. Clin Pharmacol Ther 96:549\u2013558. https:\/\/doi.org\/10.1038\/clpt.2014.155","journal-title":"Clin Pharmacol Ther"},{"key":"10010_CR56","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.hrthm.2011.03.045","volume":"8","author":"C Antzelevitch","year":"2011","unstructured":"Antzelevitch C, Burashnikov A, Sicouri S, Belardinelli L (2011) Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm 8:1281\u20131290. https:\/\/doi.org\/10.1016\/j.hrthm.2011.03.045","journal-title":"Heart Rhythm"},{"key":"10010_CR57","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2165\/11598160-000000000-00000","volume":"35","author":"JE Tisdale","year":"2012","unstructured":"Tisdale JE, Wroblewski HA, Overholser BR et al (2012) Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US. Drug Saf 35:459\u2013470. https:\/\/doi.org\/10.2165\/11598160-000000000-00000","journal-title":"Drug Saf"},{"key":"10010_CR58","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/j.1445-5994.2011.02447.x","volume":"42","author":"M Pasquier","year":"2012","unstructured":"Pasquier M, Pantet O, Hugli O et al (2012) Prevalence and determinants of QT interval prolongation in medical inpatients. Intern Med J 42:933\u2013940. https:\/\/doi.org\/10.1111\/j.1445-5994.2011.02447.x","journal-title":"Intern Med J"},{"key":"10010_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0199028","volume":"13","author":"FM Fernandes","year":"2018","unstructured":"Fernandes FM, Silva EP, Martins RR, Oliveira AG (2018) QTc interval prolongation in critically ill patients: Prevalence, risk factors and associated medications. PLoS ONE 13:1\u201312. https:\/\/doi.org\/10.1371\/journal.pone.0199028","journal-title":"PLoS ONE"},{"key":"10010_CR60","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/J.IJCARD.2017.05.072","volume":"243","author":"E Vandael","year":"2017","unstructured":"Vandael E, Vandenberk B, Vandenberghe J et al (2017) Incidence of torsade de pointes in a tertiary hospital population. Int J Cardiol 243:511\u2013515. https:\/\/doi.org\/10.1016\/J.IJCARD.2017.05.072","journal-title":"Int J Cardiol"},{"key":"10010_CR61","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.109.192704","volume":"121","author":"BJ Drew","year":"2010","unstructured":"Drew BJ, Ackerman MJ, Funk M et al (2010) Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 121:1047\u20131060. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.192704","journal-title":"Circulation"},{"key":"10010_CR62","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jacc.2005.08.067","volume":"47","author":"SMJM Straus","year":"2006","unstructured":"Straus SMJM, Kors JA, De Bruin ML et al (2006) Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 47:362\u2013367. https:\/\/doi.org\/10.1016\/j.jacc.2005.08.067","journal-title":"J Am Coll Cardiol"},{"key":"10010_CR63","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1007\/s00392-023-02173-9","volume":"112","author":"\u00d2 Mir\u00f3","year":"2023","unstructured":"Mir\u00f3 \u00d2, Aguil\u00f3 O, Trull\u00e0s JC et al (2023) QT interval and short-term outcome in acute heart failure. Clin Res Cardiol 112:1754\u20131765. https:\/\/doi.org\/10.1007\/s00392-023-02173-9","journal-title":"Clin Res Cardiol"},{"key":"10010_CR64","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/00005792-200307000-00007","volume":"82","author":"D Zeltser","year":"2003","unstructured":"Zeltser D, Justo D, Halkin A et al (2003) Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Med (Baltim) 82:282\u2013290. https:\/\/doi.org\/10.1097\/00005792-200307000-00007","journal-title":"Med (Baltim)"},{"key":"10010_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcvm.2015.00026","volume":"2","author":"PE Lazzerini","year":"2015","unstructured":"Lazzerini PE, Capecchi PL, Laghi-Pasini F (2015) Long QT syndrome: an emerging role for inflammation and immunity. Front Cardiovasc Med 2:1\u201317. https:\/\/doi.org\/10.3389\/fcvm.2015.00026","journal-title":"Front Cardiovasc Med"},{"key":"10010_CR66","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1055\/s-0043-105275","volume":"49","author":"L Kannan","year":"2017","unstructured":"Kannan L, Kotus-Bart J, Amanullah A (2017) Prevalence of cardiac arrhythmias in hypothyroid and euthyroid patients. Horm Metab Res 49:430\u2013433. https:\/\/doi.org\/10.1055\/s-0043-105275","journal-title":"Horm Metab Res"},{"key":"10010_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-04659-w","author":"A Ulivieri","year":"2022","unstructured":"Ulivieri A, Lavra L, Magi F et al (2022) Thyroid hormones regulate cardiac repolarization and QT-interval related gene expression in HiPSC cardiomyocytes. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-021-04659-w","journal-title":"Sci Rep"},{"key":"10010_CR68","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.4239\/wjd.v14.i8.1163","volume":"14","author":"D-K Sun","year":"2023","unstructured":"Sun D-K, Zhang N, Liu Y et al (2023) Dysglycemia and arrhythmias. World J Diabetes 14:1163\u20131177. https:\/\/doi.org\/10.4239\/wjd.v14.i8.1163","journal-title":"World J Diabetes"},{"key":"10010_CR69","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/jcph.322","volume":"54","author":"P Zuo","year":"2014","unstructured":"Zuo P, Haberer LJ, Fang L et al (2014) Integration of modeling and simulation to support changes to Ondansetron dosing following a randomized, double-blind, placebo-, and active-controlled thorough QT study. J Clin Pharmacol 54:1221\u20131229. https:\/\/doi.org\/10.1002\/jcph.322","journal-title":"J Clin Pharmacol"},{"key":"10010_CR70","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S0009-9236(98)90137-0","volume":"64","author":"AD Van Haarst","year":"1998","unstructured":"Van Haarst AD, Van \u2019T, Klooster GAE, Van Gerven JMA et al (1998) The influence of Cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 64:542\u2013546. https:\/\/doi.org\/10.1016\/S0009-9236(98)90137-0","journal-title":"Clin Pharmacol Ther"},{"key":"10010_CR71","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/cpt.1647","volume":"107","author":"Z Li","year":"2020","unstructured":"Li Z, Mirams GR, Yoshinaga T et al (2020) General principles for the validation of proarrhythmia risk prediction models: an extension of the CiPA in silico strategy. Clin Pharmacol Ther 107:102\u2013111. https:\/\/doi.org\/10.1002\/cpt.1647","journal-title":"Clin Pharmacol Ther"},{"key":"10010_CR72","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/phar.2087","volume":"38","author":"DF Lehmann","year":"2018","unstructured":"Lehmann DF, Eggleston WD, Wang D (2018) Validation and clinical utility of the hERG IC50:Cmax ratio to determine the risk of drug-induced torsades de pointes: a meta-analysis. Pharmacotherapy 38:341\u2013348. https:\/\/doi.org\/10.1002\/phar.2087","journal-title":"Pharmacotherapy"},{"key":"10010_CR73","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.drudis.2016.02.003","volume":"21","author":"MR Davies","year":"2016","unstructured":"Davies MR, Wang K, Mirams GR et al (2016) Recent developments in using mechanistic cardiac modelling for drug safety evaluation. Drug Discov Today 21:924\u2013938. https:\/\/doi.org\/10.1016\/j.drudis.2016.02.003","journal-title":"Drug Discov Today"},{"key":"10010_CR74","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1365-2125.2012.04415.x","volume":"75","author":"RR Shah","year":"2013","unstructured":"Shah RR (2013) Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter? Br J Clin Pharmacol 75:347\u2013358. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04415.x","journal-title":"Br J Clin Pharmacol"},{"key":"10010_CR75","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40264-015-0316-6","volume":"38","author":"MN Niemeijer","year":"2015","unstructured":"Niemeijer MN, van den Berg ME, Eijgelsheim M et al (2015) Pharmacogenetics of drug-induced QT interval prolongation: an update. Drug Saf 38:855\u2013867. https:\/\/doi.org\/10.1007\/s40264-015-0316-6","journal-title":"Drug Saf"},{"key":"10010_CR76","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/psp4.12085","volume":"5","author":"L Kervezee","year":"2016","unstructured":"Kervezee L, Gotta V, Stevens J et al (2016) Levofloxacin-induced Qtc prolongation depends on the time of drug administration. CPT: Pharmacometrics & Systems Pharmacology 5:466\u2013474. https:\/\/doi.org\/10.1002\/psp4.12085","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"key":"10010_CR77","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2217\/pgs-2022-0027","volume":"23","author":"AI Lopez-Medina","year":"2022","unstructured":"Lopez-Medina AI, Chahal CAA, Luzum JA (2022) The genetics of drug-induced QT prolongation: evaluating the evidence for pharmacodynamic variants. Pharmacogenomics 23:543\u2013557. https:\/\/doi.org\/10.2217\/pgs-2022-0027","journal-title":"Pharmacogenomics"},{"key":"10010_CR78","doi-asserted-by":"publisher","unstructured":"Khan SA, Emmanuel S, Shantha Kumar V et al (2024) Long QT syndrome with drugs used in the management of arrhythmias: A systematic review. Cureus 16. https:\/\/doi.org\/10.7759\/cureus.65857","DOI":"10.7759\/cureus.65857"},{"key":"10010_CR79","doi-asserted-by":"publisher","first-page":"705","DOI":"10.5414\/CP202337","volume":"53","author":"T Jackson","year":"2015","unstructured":"Jackson T, Kondic J, Seebeck J (2015) QT-prolonging effects of monoclonal antibody drugs in humans: a systematic review of two literature and a public adverse event database. Int J Clin Pharmacol Ther 53:705\u2013711. https:\/\/doi.org\/10.5414\/CP202337","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10010_CR80","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.vascn.2008.04.001","volume":"58","author":"HM Vargas","year":"2008","unstructured":"Vargas HM, Bass AS, Breidenbach A et al (2008) Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. J Pharmacol Toxicol Methods 58:72\u201376. https:\/\/doi.org\/10.1016\/j.vascn.2008.04.001","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10010_CR81","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1136\/postgradmedj-2020-138661","volume":"97","author":"R Khatib","year":"2021","unstructured":"Khatib R, Sabir FRN, Omari C et al (2021) Managing drug-induced QT prolongation in clinical practice. Postgrad Med J 97:452\u2013458. https:\/\/doi.org\/10.1136\/postgradmedj-2020-138661","journal-title":"Postgrad Med J"},{"key":"10010_CR82","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.tcm.2017.07.010","volume":"28","author":"RL Woosley","year":"2018","unstructured":"Woosley RL, Black K, Heise CW, Romero K (2018) CredibleMeds.org: what does it offer? Trends Cardiovasc Med 28:94\u201399. https:\/\/doi.org\/10.1016\/j.tcm.2017.07.010","journal-title":"Trends Cardiovasc Med"},{"key":"10010_CR83","doi-asserted-by":"publisher","unstructured":"Chien HT, Lin FJ, Juang JMJ, Lin SW (2024) The impact of QT-Prolonging medications and Drug\u2013Drug interactions on QTc interval prolongation in hospitalized patients: A Case-Crossover study. https:\/\/doi.org\/10.1002\/cpt.3469. Clin Pharmacol Ther","DOI":"10.1002\/cpt.3469"},{"key":"10010_CR84","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/bcp.14951","volume":"88","author":"MI Then","year":"2022","unstructured":"Then MI, Andrikyan W, Maas R, Fromm MF (2022) The CredibleMeds\u00ae list: usage of QT interval prolonging drugs in Germany and discordances with prescribing information. Br J Clin Pharmacol 88:226\u2013236. https:\/\/doi.org\/10.1111\/bcp.14951","journal-title":"Br J Clin Pharmacol"},{"key":"10010_CR85","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s12012-024-09873-2","volume":"24","author":"OE Ojo","year":"2024","unstructured":"Ojo OE, Ajayi EA, Ajayi AO et al (2024) Determinants\/predictors of QT abnormalities in patients on psychotropic medications in a Nigerian tertiary hospital. Cardiovasc Toxicol 24:700\u2013709. https:\/\/doi.org\/10.1007\/s12012-024-09873-2","journal-title":"Cardiovasc Toxicol"},{"key":"10010_CR86","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1007\/s00213-017-4685-7","volume":"234","author":"A Ojero-Senard","year":"2017","unstructured":"Ojero-Senard A, Benevent J, Bondon-Guitton E et al (2017) A comparative study of QT prolongation with serotonin reuptake inhibitors. Psychopharmacology 234:3075\u20133081. https:\/\/doi.org\/10.1007\/s00213-017-4685-7","journal-title":"Psychopharmacology"},{"key":"10010_CR87","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1161\/CIRCOUTCOMES.113.000651","volume":"7","author":"JE Tisdale","year":"2014","unstructured":"Tisdale JE, Jaynes HA, Kingery JR et al (2014) Effectiveness of a clinical decision support system for reducing the risk of Qt interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 7:381\u2013390. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.113.000651","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10010_CR88","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1161\/CIRCOUTCOMES.113.000152","volume":"6","author":"JE Tisdale","year":"2013","unstructured":"Tisdale JE, Jaynes HA, Kingery JR et al (2013) Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 6:479\u2013487. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.113.000152","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-025-10010-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-025-10010-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-025-10010-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T10:18:57Z","timestamp":1764929937000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-025-10010-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":88,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10010"],"URL":"https:\/\/doi.org\/10.1007\/s10928-025-10010-x","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}